Please assess the completion status of the following clinical trial:

Trial Title: A Study of UCB and MSCs in Children With CP: ACCeNT-CP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥24 months and ≤60 months adjusted age at the time of enrollment.~2. Diagnosis: Unilateral or bilateral hypertonic cerebral palsy secondary to in utero or perinatal stroke/hemorrhage, hypoxic ischemic encephalopathy (including, but not limited to, birth asphyxia), and/or periventricular leukomalacia.~3. Performance status: Gross Motor Function Classification Score levels I - IV~4. Review of brain imaging (obtained as standard of care prior to study entry) does not suggest a genetic condition or brain malformation.~5. Legal authorized representative consent.~Exclusion Criteria:~1. Available qualified autologous cord blood unit.~2. Hypotonic or ataxic cerebral palsy without spasticity.~3. Autism and autistic spectrum disorders.~4. Hypsarrhythmia.~5. Legally blind~6. Intractable seizures causing epileptic encephalopathy.~7. Evidence of a progressive neurologic disease.~8. Has an active, uncontrolled systemic infection or documentation of HIV+ status.~9. Known genetic disease or phenotypic evidence of a genetic disease on physical exam.~10. Concurrent genetic or acquired disease or comorbidity(ies) that could require a future allogeneic stem cell transplant.~11. Requires ventilatory support, including home ventilator, CPAP, BiPAP, or supplemental oxygen.~12. Impaired renal or liver function as determined by serum creatinine \>1.5mg/dL and/or total bilirubin \>1.3mg/dL except in patients with known Gilbert's disease.~13. Possible immunosuppression, defined as WBC \<3,000 cells/mL or absolute lymphocyte count (ALC) \<1500 with abnormal T-cell subsets.~14. Patient's medical condition does not permit safe travel.~15. Previously received any form of cellular therapy.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 60 Months
- Healthy Volunteers: f

Study Arms:
- Allogeneic Umbilical Cord Blood (Type: EXPERIMENTAL): Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
- Cord Tissue Mesenchymal Stromal Cells (Type: EXPERIMENTAL): Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
- Natural History (Type: ACTIVE_COMPARATOR): Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).